CenterHigh
Financial Times - CompaniesNews report · Jul 9, 7:35 AM
Astra Zeneca shares slide 9% after heart treatment disappoints in trial
UK pharmaceutical company says Wainua drug did not meet goal of reducing cardiovascular deaths
← Today's headlines
3 sources checked · source map still forming · 30m ago
Needs Review
Astra Zeneca shares slide 9% after heart treatment disappoints in trial
UK pharmaceutical company says Wainua drug did not meet goal of reducing cardiovascular deaths
0 Left3 Center0 Right
NEEDS REVIEW
As of July 9, 2026 at 9:13 AM, this is how Optics News reads the wording differences in this story.
What happened UK pharmaceutical company says Wainua drug did not meet goal of reducing cardiovascular deaths.
The headline split Financial Times - Companies frames it as "Astra Zeneca shares slide 9% after heart treatment disappoints in trial". CNBC frames it as "Astra Zeneca stock dives 9% after heart drug trial misses target".
Match confidence Developing. Only 3 sources are matched, and the source map is still narrow. Useful to watch, not enough to draw conclusions yet.
Same-event confidenceDeveloping
Not enough sources yet to confirm this is the same specific event.
Wording differs, but the match is too narrow to read confidently yet.
WHAT EACH SIDE EMPHASIZED
Left / center-leftNo matching source in this bucket yet.
Optics keeps watching for pickup.
CenterAstra Zeneca shares slide 9% after heart treatment disappoints in trial
Financial Times - Companies · Center · News report
Right / center-rightNo matching source in this bucket yet.
Optics keeps watching for pickup.
SEE THE HEADLINES
Open source
CenterHigh
STAT NewsNews report · Jul 9, 9:13 AM
STAT+: Astra Zeneca, Ionis report major trial failure with heart disease drug
stationismajorfailure
Astra Zeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drugmakers.
CenterMostly Factual
CNBCNews report · Jul 9, 7:59 AM
Astra Zeneca stock dives 9% after heart drug trial misses target
stockdivesaftermissestarget
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
DetailsScore hidden · 3 sources · 1 bias buckets
Score hidden until the match is cleanerLow confidence3 sources · 1 bias bucketsDeveloping · 3 sources · 1 bucketFormats: News report
SOURCE MAP CHANGES
Jul 9, 7:35 AM: Financial Times - Companies joined the source map.
Jul 9, 7:59 AM: CNBC joined the source map.
Jul 9, 9:13 AM: STAT News joined the source map.
Now: score hidden until the source match is cleaner. Story health is developing · 3 sources · 1 bucket.